Reimagining diversity in multiple myeloma clinical trials

Saved in:
Bibliographic Details
Published in:Hematological oncology 2022-10, Vol.40 (4), p.689-694
Main Authors: Habr, Dany, Corsaro, Massimo
Format: Article
Language:English
Subjects:
Clinical trials
disparity
diversity
Humans
Multiple myeloma
Multiple Myeloma - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3
cites cdi_FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3
container_end_page 694
container_issue 4
container_start_page 689
container_title Hematological oncology
container_volume 40
creator Habr, Dany
Corsaro, Massimo
description
doi_str_mv 10.1002/hon.2997
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9790672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2721474035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3</originalsourceid><addsrcrecordid>eNp1kU1LAzEQhoMotn6Av0AWvHhZzWa3meQiiPgFxYLoOaTpbJuS3a3JbqX_3tRqUcHTHObh4Z15CTnJ6EVGKbucNfUFkxJ2SD-jUqYZ5XKX9CkDkVKWsx45CGFOadxRsU96-SCXWSF5n8hntJWe2trW02Ril-iDbVeJrZOqc61dOEyqFbqm0olxkTLaJa232oUjslfGgcdf85C83t2-3Dykw9H94831MDU5F5AWZZlNODIBY6HBFJxxlNKUIAEBWGE4BZ4jaCaBw9jkgo8ZHwgtBB2gMfkhudp4F924wonBuvXaqYWPuf1KNdqq35vaztS0WSoJknJgUXD-JfDNW4ehVZUNBp3TNTZdUIwXQtL1OyJ69gedN52v43mKAcsKKGh83VZofBOCx3IbJqNq3YeKfah1HxE9_Rl-C34XEIF0A7xbh6t_Reph9PQp_ADM2JQX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721474035</pqid></control><display><type>article</type><title>Reimagining diversity in multiple myeloma clinical trials</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Habr, Dany ; Corsaro, Massimo</creator><creatorcontrib>Habr, Dany ; Corsaro, Massimo</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2997</identifier><identifier>PMID: 35391496</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Clinical trials ; disparity ; diversity ; Humans ; Multiple myeloma ; Multiple Myeloma - drug therapy</subject><ispartof>Hematological oncology, 2022-10, Vol.40 (4), p.689-694</ispartof><rights>2022 Pfizer Inc. Hematological Oncology published by John Wiley &amp; Sons Ltd.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3</citedby><cites>FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3</cites><orcidid>0000-0002-3361-6309</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35391496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Habr, Dany</creatorcontrib><creatorcontrib>Corsaro, Massimo</creatorcontrib><title>Reimagining diversity in multiple myeloma clinical trials</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><subject>Clinical trials</subject><subject>disparity</subject><subject>diversity</subject><subject>Humans</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kU1LAzEQhoMotn6Av0AWvHhZzWa3meQiiPgFxYLoOaTpbJuS3a3JbqX_3tRqUcHTHObh4Z15CTnJ6EVGKbucNfUFkxJ2SD-jUqYZ5XKX9CkDkVKWsx45CGFOadxRsU96-SCXWSF5n8hntJWe2trW02Ril-iDbVeJrZOqc61dOEyqFbqm0olxkTLaJa232oUjslfGgcdf85C83t2-3Dykw9H94831MDU5F5AWZZlNODIBY6HBFJxxlNKUIAEBWGE4BZ4jaCaBw9jkgo8ZHwgtBB2gMfkhudp4F924wonBuvXaqYWPuf1KNdqq35vaztS0WSoJknJgUXD-JfDNW4ehVZUNBp3TNTZdUIwXQtL1OyJ69gedN52v43mKAcsKKGh83VZofBOCx3IbJqNq3YeKfah1HxE9_Rl-C34XEIF0A7xbh6t_Reph9PQp_ADM2JQX</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Habr, Dany</creator><creator>Corsaro, Massimo</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3361-6309</orcidid></search><sort><creationdate>202210</creationdate><title>Reimagining diversity in multiple myeloma clinical trials</title><author>Habr, Dany ; Corsaro, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical trials</topic><topic>disparity</topic><topic>diversity</topic><topic>Humans</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Habr, Dany</creatorcontrib><creatorcontrib>Corsaro, Massimo</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley-Blackwell Free Backfiles(OpenAccess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Habr, Dany</au><au>Corsaro, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reimagining diversity in multiple myeloma clinical trials</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2022-10</date><risdate>2022</risdate><volume>40</volume><issue>4</issue><spage>689</spage><epage>694</epage><pages>689-694</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35391496</pmid><doi>10.1002/hon.2997</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3361-6309</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-0232
ispartof Hematological oncology, 2022-10, Vol.40 (4), p.689-694
issn 0278-0232
1099-1069
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9790672
source Wiley-Blackwell Read & Publish Collection
subjects Clinical trials
disparity
diversity
Humans
Multiple myeloma
Multiple Myeloma - drug therapy
title Reimagining diversity in multiple myeloma clinical trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A34%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reimagining%20diversity%20in%20multiple%20myeloma%20clinical%20trials&rft.jtitle=Hematological%20oncology&rft.au=Habr,%20Dany&rft.date=2022-10&rft.volume=40&rft.issue=4&rft.spage=689&rft.epage=694&rft.pages=689-694&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2997&rft_dat=%3Cproquest_pubme%3E2721474035%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3687-4ff1d6e287b8a7c4626e99cf797e7724c60763e7a29767bc386b2658a8805ecc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2721474035&rft_id=info:pmid/35391496&rfr_iscdi=true